A three-judge panel of the 5th U.S. Circuit Court of Appeals unanimously blocked a federal rule Friday that allowed mifepristone, a key abortion pill, to be prescribed via telehealth and mailed nationwide. The New Orleans-based court reinstated requirements that patients obtain the drug only in person from certified physicians, effectively ending mail-order access across the United States.

The ruling stemmed from a lawsuit filed by Louisiana against the Food and Drug Administration. The state argued that the FDA's 2023 regulations, which relaxed in-person dispensing rules originally set when mifepristone was approved in 2000, enabled out-of-state doctors to ship the pill into Louisiana in violation of its abortion ban. A co-plaintiff, a woman who claimed she was coerced into taking mailed mifepristone, joined the suit. The court wrote that the policy "creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law" and undermines the state's view that "every unborn child is a human being from the moment of conception."

Circuit Judge Kyle Duncan, a Trump appointee, authored the opinion, joined by Judges Kurt Engelhardt, also Trump-appointed, and Leslie Southwick, a George W. Bush appointee. The panel rejected arguments from mifepristone manufacturers Danco Laboratories and GenBioPro, as well as the Trump administration's request to pause the case pending an FDA safety review.

The decision follows a Western District of Louisiana ruling last month by Judge David C. Joseph, who expressed sympathy for the state's position but held off on an injunction to allow the FDA time for review. Those rules originated during the COVID-19 pandemic under President Joe Biden and persisted after the Supreme Court's 2022 Dobbs decision overturned Roe v. Wade, making medication abortion, which accounts for 63% of U.S. procedures in 2023, a primary option even in ban states.

The Supreme Court in 2024 preserved broad access to Mifepristone by ruling that anti-abortion doctors lacked standing to challenge FDA approvals. Friday's order, however, focuses on state sovereignty over distribution methods.

Advocates on both sides reacted swiftly. GenBioPro CEO Evan Masingill called the decision an alarm over ignored "FDA’s rigorous science and decades of safe use." ACLU attorney Julia Kaye warned it would harm rural patients, low-income individuals, people with disabilities, and survivors of intimate partner violence nationwide. Anti-abortion groups hailed it as ending "mail-order abortion," with Americans United for Life predicting the practice's demise.

The ruling also affects miscarriage management, as mifepristone treats that condition. About 25% of medication abortions previously relied on telehealth. Experts anticipate an immediate appeal to the Supreme Court, potentially pausing the order within weeks. Similar suits from states like Idaho, Kansas, Missouri, Florida, and Texas are ongoing.